MedTrace Logo

Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus

NCT00565162 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2008-08-25

No results posted yet for this study

Summary

To introduce initiation of glargine insulin treatment in primary care based on a patient education program. To show and compare feasibility of group education to individual education program.

Conditions

Interventions

DRUG

Insulin Glargine

Insulin glargine administered by subcutaneous injection daily at bedtime for 24 weeks.

Sponsors & Collaborators

Principal Investigators

  • Sanni Lahdenpera · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Completion
2005-06-30

Countries

  • Finland
  • Netherlands
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00565162 on ClinicalTrials.gov